KR20110043654A - 폰 빌레브란트 인자 또는 제ⅷ 인자 및 혈소판의 억제제에 의하여 유도된 응고장애 치료용 폰 빌레브란트 인자 - Google Patents

폰 빌레브란트 인자 또는 제ⅷ 인자 및 혈소판의 억제제에 의하여 유도된 응고장애 치료용 폰 빌레브란트 인자 Download PDF

Info

Publication number
KR20110043654A
KR20110043654A KR1020117002934A KR20117002934A KR20110043654A KR 20110043654 A KR20110043654 A KR 20110043654A KR 1020117002934 A KR1020117002934 A KR 1020117002934A KR 20117002934 A KR20117002934 A KR 20117002934A KR 20110043654 A KR20110043654 A KR 20110043654A
Authority
KR
South Korea
Prior art keywords
vwf
fviii
factor
platelet
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117002934A
Other languages
English (en)
Korean (ko)
Inventor
게르하르트 디크나이테
잉고 프라그스트
엔히크 레싸
토르슈텐 하스
슈테판 차이틀러
Original Assignee
체에스엘 베링 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20110043654(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 체에스엘 베링 게엠베하 filed Critical 체에스엘 베링 게엠베하
Publication of KR20110043654A publication Critical patent/KR20110043654A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020117002934A 2008-07-10 2009-07-10 폰 빌레브란트 인자 또는 제ⅷ 인자 및 혈소판의 억제제에 의하여 유도된 응고장애 치료용 폰 빌레브란트 인자 Ceased KR20110043654A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008032361A DE102008032361A1 (de) 2008-07-10 2008-07-10 Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
DE102008032361.6 2008-07-10

Publications (1)

Publication Number Publication Date
KR20110043654A true KR20110043654A (ko) 2011-04-27

Family

ID=41171229

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117002934A Ceased KR20110043654A (ko) 2008-07-10 2009-07-10 폰 빌레브란트 인자 또는 제ⅷ 인자 및 혈소판의 억제제에 의하여 유도된 응고장애 치료용 폰 빌레브란트 인자

Country Status (13)

Country Link
US (2) US8603979B2 (https=)
EP (1) EP2310043B2 (https=)
JP (1) JP5653916B2 (https=)
KR (1) KR20110043654A (https=)
CN (1) CN102088999A (https=)
AU (1) AU2009268289B2 (https=)
CA (1) CA2730290C (https=)
DE (1) DE102008032361A1 (https=)
DK (1) DK2310043T4 (https=)
ES (1) ES2395855T5 (https=)
PL (1) PL2310043T5 (https=)
RU (1) RU2563236C2 (https=)
WO (1) WO2010003687A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN105816858B (zh) 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
KR20160104740A (ko) * 2008-06-24 2016-09-05 옥타파마 아게 응고 인자 ｖｉｉｉ을 정제하는 방법
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CN103263663B (zh) * 2013-06-08 2016-05-04 兆科药业（合肥）有限公司 一种抗血小板溶栓素在制备治疗vwf缺陷型血管栓塞性疾病的药物中的应用
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US6518482B2 (en) * 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
WO2001047547A1 (en) † 1999-12-24 2001-07-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
JP2011527301A (ja) 2011-10-27
DE102008032361A1 (de) 2010-01-21
US20110112023A1 (en) 2011-05-12
EP2310043B2 (en) 2022-05-18
ES2395855T3 (es) 2013-02-15
US20140128325A1 (en) 2014-05-08
DK2310043T4 (da) 2022-06-20
RU2011104705A (ru) 2012-08-20
JP5653916B2 (ja) 2015-01-14
CA2730290C (en) 2017-02-07
AU2009268289B2 (en) 2014-11-06
US8603979B2 (en) 2013-12-10
PL2310043T5 (pl) 2024-02-05
PL2310043T3 (pl) 2013-02-28
RU2563236C2 (ru) 2015-09-20
CA2730290A1 (en) 2010-01-14
DK2310043T3 (da) 2013-01-07
CN102088999A (zh) 2011-06-08
EP2310043A1 (en) 2011-04-20
EP2310043B1 (en) 2012-09-19
US9095564B2 (en) 2015-08-04
WO2010003687A1 (en) 2010-01-14
AU2009268289A1 (en) 2010-01-14
ES2395855T5 (es) 2022-09-06

Similar Documents

Publication Publication Date Title
JP5653916B2 (ja) 血小板のインヒビターにより誘発される凝固障害を治療するためのフォン・ヴィレブランド因子または第ｖｉｉｉ因子およびフォン・ヴィレブランド因子
Svensson et al. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding
Moore et al. Does tranexamic acid improve clot strength in severely injured patients who have elevated fibrin degradation products and low fibrinolytic activity, measured by thrombelastography?
US20100298223A1 (en) Fibrinogen for treatment of bleeding in trauma and platelet disorders
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
US20030180282A1 (en) Method of treatment of thrombotic events
RU2290195C1 (ru) Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями
HU219595B (hu) Von Willebrand-faktort tartalmazó koncentrátumok alkalmazása trombózis elleni szerek és/vagy fibrinotikus szerek okozta vérzésnél antidotumként ható szer előállítására
Levy et al. Perioperative coagulation management in the intensive care unit
Levy Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas
Levy et al. Anesthetic concerns for patients with coagulopathy
KR20120022717A (ko) 피브리노겐의 신규 용도
Taylor Antiinflammatory effects of aprotinin
Zotz et al. Procoagulant drugs
Agostini et al. Blood Products, Derivates, and Prohemostatic Drugs
Lethagen et al. On the use of desmopressin in von Willebrand disease
Jungwirth et al. Xenon and Air Bubble Injection during Cardiopulmonary Bypass
Marcucci et al. 11 Hematologic Risk Assessment
Hong et al. Glycoprotein IIb/IIIa Receptor Antagonist CRL42796, in Combination with Aspirin and/or Enoxaparin, Prevents Coronary Artery Rethrombosis after Successful Thrombolytic Treatment by Recombinant Tissue Plasminogen Activator (rt-PA)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150831

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160519

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150831

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160818

PJ0201 Trial against decision of rejection

Patent event date: 20160818

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20160519

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20161021

Appeal identifier: 2016101004838

Request date: 20160818

J801 Dismissal of trial

Free format text: TRIAL NUMBER: 2016101004838; REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160818

Effective date: 20161021

PJ0801 Rejection of trial

Patent event date: 20161021

Patent event code: PJ08011S01D

Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision)

Decision date: 20161021

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016101004838

Request date: 20160818